CAU
SUPN icon

Caxton Associates (UK)’s Supernus Pharmaceuticals SUPN Stock Holding History

Caxton Associates (UK)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-113,093
Closed -$5.62M – 993
2025
Q4 		$5.62M Buy
113,093
+89,710
+384% +$4.36M 0.11% 56
2025
Q3 		$1.12M Buy
+23,383
New +$942K 0.03% 315

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (UK)'s SUPN Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 113,093 shares — an estimated $5.62M sold.

Caxton Associates (UK) first reported a position in SUPN in Q3 2025 and held it in 2 quarters. The position peaked at $5.62M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 113,093 Supernus Pharmaceuticals shares in Q1 2026, an estimated $5.62M.
  • Caxton Associates (UK) first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Supernus Pharmaceuticals position peaked at $5.62M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.